We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Section: Clinical Updates

Clinically Meaningful Changes in Cognitive and Functional Measures Early in Alzheimer’s Disease: Insights from Population-Based Cohorts

MedXY Editorial Team•Oct 9, 2025•Clinical Updates
Alzheimer's diseasecognitive agingmild cognitive impairment

Highlights

  • Population-based studies reveal specific thresholds of meaningful within-patient change on commonly used clinical outcome assessments (COAs) in early cognitive impairment.
  • Annualized change thresholds for CDR scale Sum of Boxes (0.49), MMSE (-1.01), and FAQ (1.04) in incident MCI offer benchmarks for interpreting clinical progression.
  • These data enhance clinical trial planning and evaluation by anchoring COA changes to clinically meaningful functional and cognitive decline early in ADRD.
  • Mechanistic insights into neurodegeneration underscore the importance of early detection and targeted interventions based on changes in cognition and function.

Background

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Related articles

Open language-specific specialty feeds and department pages.

Integrating Plasma p-tau217 and APOE Genotype to Predict Cognitive Decline Across Diverse PopulationsThis pooled analysis of seven multi-ethnic cohorts demonstrates the combined prognostic value of plasma phosphorylated tau 217 concentrations and APOE-ε4 genotype for predicting risk and timing of cognitive impairment, emphasizing biomarkerSep 13, 2026Unraveling Alzheimer’s Disease Progression in Down Syndrome via Blood Proteome DynamicsLongitudinal analysis of blood proteins reveals distinctive trajectories and associations with cognitive decline in adults with Down syndrome, shedding light on Alzheimer’s disease pathophysiology in this high-risk group.Sep 5, 2026MRI-Derived EOAD-Signature Atrophy as a Prognostic Biomarker in Early-Onset Mild Cognitive ImpairmentBaseline cortical atrophy within an EOAD-specific brain signature predicts progression from mild cognitive impairment to dementia, providing a valuable MRI biomarker for individualized prognosis in early-onset Alzheimer disease.Aug 28, 2026
Loading comments...
MedXY briefing

Get the free newsletter

Evidence-led clinical news, trends, and analysis—delivered to your inbox.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
Plasma Biomarkers for Neocortical Tau Burden
A multiprotein plasma panel improves detection of advanced neocortical tau pathology in Alzheimer’s disease risk individuals beyond p-tau217 alone, enhancing patient stratification and clinical trial selection.
Aug 15, 2026
Oral Anticoagulants, Cognition, and Clinical Outcomes in Atrial Fibrillation and Alzheimer’s Disease: Insights from a Swedish Nationwide StudyThis review synthesizes evidence linking NOAC use to slower cognitive decline and improved clinical outcomes in patients with atrial fibrillation and Alzheimer’s disease, highlighting advantages over warfarin and non-use.Aug 13, 2026
Discriminating Prion Diseases from Alzheimer’s Disease Using Plasma Biomarkers: The Crucial Role of NfL/p-tau217 RatioPlasma phosphorylated tau biomarkers overlap in Alzheimer’s and prion diseases, risking diagnostic confusion. The NfL/p-tau217 ratio emerges as an accurate plasma biomarker to distinguish prion diseases from Alzheimer’s, improving diagnostiJul 14, 2026